Person:
ÖZER, SIDIKA AYŞE

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

ÖZER

First Name

SIDIKA AYŞE

Name

Search Results

Now showing 1 - 10 of 19
  • PublicationOpen Access
    Identification of Differentially Expressed IGFBP5-Related Genes in Breast Cancer Tumor Tissues Using cDNA Microarray Experiments
    (MDPI AG, 2015-11-10) GÜLLÜ AMURAN, GÖKÇE; Akkiprik, Mustafa; Peker, Irem; Ozmen, Tolga; Amuran, Gokce Gullu; Gulluoglu, Bahadir M.; Kaya, Handan; Ozer, Ayse
    IGFBP5 is an important regulatory protein in breast cancer progression. We tried to identify differentially expressed genes (DEGs) between breast tumor tissues with IGFBP5 overexpression and their adjacent normal tissues. In this study, thirty-eight breast cancer and adjacent normal breast tissue samples were used to determine IGFBP5 expression by qPCR. cDNA microarrays were applied to the highest IGFBP5 overexpressed tumor samples compared to their adjacent normal breast tissue. Microarray analysis revealed that a total of 186 genes were differentially expressed in breast cancer compared with normal breast tissues. Of the 186 genes, 169 genes were downregulated and 17 genes were upregulated in the tumor samples. KEGG pathway analyses showed that protein digestion and absorption, focal adhesion, salivary secretion, drug metabolism-cytochrome P450, and phenylalanine metabolism pathways are involved. Among these DEGs, the prominent top two genes (MMP11 and COL1A1) which potentially correlated with IGFBP5 were selected for validation using real time RT-qPCR. Only COL1A1 expression showed a consistent upregulation with IGFBP5 expression and COL1A1 and MMP11 were significantly positively correlated. We concluded that the discovery of coordinately expressed genes related with IGFBP5 might contribute to understanding of the molecular mechanism of the function of IGFBP5 in breast cancer. Further functional studies on DEGs and association with IGFBP5 may identify novel biomarkers for clinical applications in breast cancer.
  • PublicationOpen Access
    GENDER DIFFERENCES IN CLINICAL FEATURES AND BURDEN IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: PRELIMINARY REPORT
    (BMJ PUBLISHING GROUP, 2021-06) DURUÖZ, MEHMET TUNCAY; Duruoz, M. T.; Ozer, A.; Gezer, H. H.; Melikoglu, M. Alkan; Hizmetli, S.; Baklacioglu, H. S.; Sahin, N.; Oz, N.; Gursoy, D. Erdem; Altintas, D.; Oba, P.; Kasman, S. Acer
  • Publication
    Impact of glucocorticoid receptor gene (NR3C1) polymorphisms in Turkish patients with metabolic syndrome
    (SPRINGER, 2016) AKKİPRİK, MUSTAFA; Kaya, Z.; Caglayan, S.; Akkiprik, M.; Aral, C.; Ozisik, G.; Ozata, M.; Ozer, A.
    Background The metabolic syndrome (MetS) is characterized by a cluster of metabolic factors, including insulin resistance and type-2 diabetes, abdominal obesity, dyslipidemia, hypertension and microalbuminuria. Impaired glucocorticoid receptor (GR) activity also plays an important role in the etiology of MetS. The objective of our study is to evaluate the effects of GR gene polymorphisms (BclI, N363S, TthIII1 and ER22/23EK) in Turkish patients with MetS. Materials and methods Seventy subjects with MetS and 185 healthy controls were enrolled in the study. PCR-RFLP analysis was used for genotyping. Results for each polymorphism have been verified by allele-specific oligonucleotide analysis. Results BclI GG genotype was significantly associated with an increased risk of MetS (p = 0.02). Also, only in women, the G allele carriers were significantly associated with higher C-peptide. T allele carriers of TthIII1 polymorphism were significantly associated with higher C-peptide, triglyceride, insulin and C-reactive protein (CRP, p value 0.048, 0.022, 0.005 and 0.022, respectively), and lower fasting blood glucose (FBG, p = 0.02). The combined carriers of BclI polymorphism G allele and TthIII1 polymorphism T allele were significantly associated with higher diastolic blood pressure in all patients, and lower FBG and postprandial blood glucose in only men. All the ER22/23EK polymorphisms coexisted with polymorphic variant of TthIII1 (p = 0.0058). Conclusion The presence of homozygote polymorphic variant of BclI might be good predictive markers for the disease susceptibility. The BclI and the TthIII1 polymorphism are associated with sex-specific clinical parameters. Our findings also suggest that the combination of BclI and TthIII1 polymorphisms may play a protective role in blood glucose.
  • PublicationOpen Access
    SUBCLINICAL INFLAMMATION AND RELATED PARAMETERS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER
    (BMJ PUBLISHING GROUP, 2020-06) DURUÖZ, MEHMET TUNCAY; Duruoz, M. T.; Oz, N.; Ozer, A.; Gezer, H. H.; Gursoy, D. Erdem; Kasman, S. Acer
  • Publication
    17Beta-estradiol modulates endothelin-1 expression and release in human endothelial cells
    (2000) ÖZER, SIDIKA AYŞE; Bilsel, A. S.; Moini, H.; Tetik, E.; Aksungar, F.; Kaynak, B.; Ozer, A.
    OBJECTIVE: In this study the role of 17beta-estradiol (E2) in the regulation of endothelin-1 (ET-1) mRNA expression and secretion was investigated in cultured human umbilical vein endothelial cells (HUVECs). METHODS: Endothelial cells were either deprived of or treated with 17beta-estradiol (10(-9), 10(-7) M) for 48 h. After the incubation, the effect of E2 on ET-1 gene expression was evaluated by Northern blot analysis. ET-1 release into the media was measured by radioimmunoassay after 6 h of incubation under basal conditions and upon stimulation with thrombin (4 U/ml). In addition, the cyclic guanosine 5'-monophosphate (cGMP) content of cells was assayed by immunoassay. In order to exclude the role of nitric oxide (NO) in E2-induced effects on endothelin-1 gene expression and secretion, nitric oxide synthase (NOS) inhibitor, N-nitro L-arginine methyl ester (1 mM) (L-NAME) was added to the media of some cultures. RESULTS: Incubation of HUVECs with 10(-9) and 10(-7) M E2 for 48 h resulted in a 30 and 47% inhibition of ET-1 mRNA expression, respectively. Incubation with E2 also decreased the basal and thrombin-stimulated ET-1 release while increasing the cGMP content of cells significantly. NOS inhibitor L-NAME increased the release of ET-1 from E2-incubated cells but did not alter the ET-1 release from hormone-deprived cells. However, ET-1 secretion of E2-treated cells were significantly less than the deprived ones. Northern blot analyses also demonstrated that inhibition of NOS only partly attenuated the effect of E2 on ET-1 gene expression. In the presence of L-NAME, treatment with 10(-7) M E2 caused a 12% decrease in ET-1 gene expression. CONCLUSION: The results demonstrate that E2 may play both direct and indirect role in regulation of ET-1 gene expression and production in human endothelial cells. E2-induced increase in NO but decrease in ET-1 production may partly explain the mechanism of the protective effects of the hormone on the cardiovascular system.
  • PublicationOpen Access
    Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer
    (BMC, 2008-08) AKKİPRİK, MUSTAFA; Akkiprik, Mustafa; Feng, Yumei; Wang, Huamin; Chen, Kexin; Hu, Limei; Sahin, Aysegul; Krishnamurthy, Savitri; Ozer, Ayse; Hao, Xishan; Zhang, Wei
    The insulin-like growth factor axis, which has been shown to protect cells from apoptosis, plays an essential role in normal cell physiology and in cancer development. The family of insulin-like growth factor binding proteins (IGFBPs) has been shown to have a diverse spectrum of functions in cell growth, death, motility, and tissue remodeling. Among the six IGFBP family members, IGFBP-5 has recently been shown to play an important role in the biology of breast cancer, especially in breast cancer metastasis
  • PublicationOpen Access
    EVALUATION OF CLINICAL FEATURES IN PATIENTS DIAGNOSED WITH JUVENILE AND ADULT-ONSET FAMILIAL MEDITERRANEAN FEVER
    (BMJ PUBLISHING GROUP, 2020-06) DURUÖZ, MEHMET TUNCAY; Gursoy, D. Erdem; Gezer, H. H.; Kasman, S. Acer; Oz, N.; Ozer, A.; Duruoz, M. T.
  • Publication
    Effect of BCG vaccination on cytokine mRNA expression in atopic children with asthma
    (2003) ÖZER, SIDIKA AYŞE; Ozer, Ayse; Tükenmez, Faruk; Biricik, Anil; Barlan, Isil B.; Cirakoglu, Beyazit; Başaran, Müjdat M.
    BACKGROUND: To investigate whether a preexisting T(H2)-type immune response could be suppressed by BCG immunization in atopic children with asthma. METHODS AND RESULTS: We have used PCR to amplify reverse transcribed (RT) IFN-gamma and IL-5 mRNA expressed by peripheral blood mononuclear cells (PBMCs) in response to in vitro phytohemagglutinin A, purified protein derivative and Dermatophagoides pteronyssinus II stimulation from nine atopic children, both before and 8 weeks after BCG vaccination. We have demonstrated that IFN-gamma expression was induced in response to all stimulants (IFN-gamma/beta-actin) after the vaccination, whereas there was no expression before (P<0.001). Although there was a tendency to diminish in the expression of IL-5 mRNA in response to the stimulants, only PHA rendered a statistically significant decrease after the vaccination. CONCLUSIONS: These results provide some evidence of TH1 dominance after BCG administration in atopic children.
  • Publication
    Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer
    (SAGE PUBLICATIONS LTD, 2016) AKKİPRİK, MUSTAFA; Dirican, Ebubekir; Akkiprik, Mustafa; Ozer, Ayse
    Breast cancer (BCa) is the most common cancer and the second cause of death among women. Phosphoinositide 3-kinase (PI3K) signaling pathway has a crucial role in the cellular processes such as cell survival, growth, division, and motility. Moreover, oncogenic mutations in the PI3K pathway generally involve the activation phosphatidylinositol-4,5-bisphosphate 3-kinase-catalytic subunit alpha (PIK3CA) mutation which has been identified in numerous BCa subtypes. In this review, correlations between PIK3CA mutations and their clinicopathological parameters on BCa will be described. It is reported that PIK3CA mutations which have been localized mostly on exon 9 and 20 hot spots are detected 25-40 % in BCa. This relatively high frequency can offer an advantage for choosing the best treatment options for BCa. PIK3CA mutations may be used as biomarkers and have been major focus of drug development in cancer with the first clinical trials of PI3K pathway inhibitors currently in progress. Screening of PIK3CA gene mutations might be useful genetic tests for targeted therapeutics or diagnosis. Increasing data about PIK3CA mutations and its clinical correlations with BCa will help to introduce new clinical applications in the near future.
  • PublicationOpen Access
    REGIONAL DIFFERENCES IN DISEASE CHARACTERISTICS OF FAMILIAL MEDITERRANEAN FEVER IN TURKEY: PRELIMINARY REPORT
    (BMJ PUBLISHING GROUP, 2021-06) DURUÖZ, MEHMET TUNCAY; Duruoz, M. T.; Gezer, H. H.; Melikoglu, M. Alkan; Hizmetli, S.; Baklacioglu, H. S.; Sahin, N.; Ozer, A.; Oz, N.; Gursoy, D. Erdem; Altintas, D.; Oba, P.; Kasman, S. Acer